Average Co-Inventor Count = 2.62
ph-index = 6
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Ablynx N.v. (10 from 163 patents)
2. Argenx Bv (3 from 28 patents)
3. Argen-x N.v. (3 from 11 patents)
4. University of Bern (2 from 17 patents)
5. New York University (1 from 1,629 patents)
6. Umc Utrecht Holding B.v. (1 from 48 patents)
7. Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (1 from 44 patents)
8. Argenx Bvba (1 from 13 patents)
9. Argenx Iip Bv (1 from 2 patents)
10. Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw (1 from 1 patent)
22 patents:
1. 12344678 - FcRn/HSA binding molecules and methods of use
2. 11571475 - Anti-CD70 and BCR-ABL inhibitor combination therapy
3. 11492401 - Therapeutic musk antibodies
4. 11434298 - Antibodies to CD70
5. 11072665 - Antibodies to CD70
6. 11034755 - Polypeptides and polypeptide constructs comprising single domain antibodies directed against von willebrand factor
7. 10391168 - Anti-CD70 combination therapy
8. 10112989 - Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
9. 9926364 - Chimeric human-llama antigens and methods of use
10. 9765148 - Antibodies to CD70
11. 9765149 - Antibodies to CD70
12. 9725522 - Pulmonary administration of immunoglobulin single variable domains and constructs thereof
13. 9371381 - Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor
14. 9320792 - Pulmonary administration of immunoglobulin single variable domains and constructs thereof
15. 9243065 - Polypeptide constructs including VHH directed against EGFR for intracellular delivery